FDA Withdraws Approval of 16 Abbreviated New Drug Applications from Elite Laboratories, Inc. and Others

Summary

The US Food and Drug Administration (FDA) has withdrawn the approval of 16 abbreviated new drug applications (ANDAs) from multiple pharmaceutical companies, including Elite Laboratories, Inc., following written notifications that the drug products are no longer commercially available.